Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Fitusiran is being developed for haemophilia A and B in partnership with RNA interference (RNAi) specialist Alnylam – but has already been affected by safety issues. Alnylam temporarily halted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback